Gisela Paulsen - Dec 16, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role: Former President and COO
Signature: /s/ Gisela Paulsen
Stock symbol: OCX
Transactions as of: Dec 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 12/20/2022, 03:05 PM
Previous filing: Aug 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCX	Common Stock, no par value	Disposed to Issuer	$0	-175K	-32.32%	$0.00	367K	Dec 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCX	Option to Purchase Common Stock	Disposed to Issuer	$0	-172K	-45.83%	$0.00	203K	Dec 16, 2022	Common Stock	172K	$3.42	Direct	F2
transaction	OCX	Option to Purchase Common Stock	Disposed to Issuer	$0	-70.3K	-56.25%	$0.00	54.7K	Dec 16, 2022	Common Stock	70.3K	$1.15	Direct	F2
transaction	OCX	Option to Purchase Common Stock	Disposed to Issuer	$0	-125K	-100%	$0.00^*	0	Dec 16, 2022	Common Stock	125K	$1.15	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining restricted stock units immediately vested on December 16, 2022.
F2	The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining options immediately vested and became exercisable as of December 16, 2022.